KDM5A Regulates a Translational Program that Controls p53 Protein Expression
Authors:
Open Access
Abstract
No abstract availableKeywords
Funding Information
- Assisi Foundation of Memphis
- American Lebanese Syrian Associated Charities
- US Public Health Service Childhood Solid Tumor Program Project (CA23099)
- National Cancer Institute (21766, R03CA212802, R01CA229739, R01CA198279, R01CA201268)
- American Cancer Society-Research Scholar (130421-RSG-17-071-01-TBG)
This publication has 75 references indexed in Scilit:
- Synthesis of Rocaglamide Hydroxamates and Related Compounds as Eukaryotic Translation Inhibitors: Synthetic and Biological StudiesJournal of Medicinal Chemistry, 2011
- A germline variant in the TP53 polyadenylation signal confers cancer susceptibilityNature Genetics, 2011
- Covalent histone modifications — miswritten, misinterpreted and mis-erased in human cancersNature Reviews Cancer, 2010
- A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell SubpopulationsCell, 2010
- The landscape of somatic copy-number alteration across human cancersNature, 2010
- The first 30 years of p53: growing ever more complexNature Reviews Cancer, 2009
- Haematopoietic malignancies caused by dysregulation of a chromatin-binding PHD fingerNature, 2009
- A microRNA component of the p53 tumour suppressor networkNature, 2007
- Histone Demethylation Mediated by the Nuclear Amine Oxidase Homolog LSD1Cell, 2004
- Cancer genes and the pathways they controlNature Medicine, 2004